source
- Sarepta receives FDA decision deadline for exon-skipping therapies, appoints Anna Protopapas as Flare CEOThe U.S. Food and Drug Administration has set a deadline for a decision on Sarepta Therapeutics' exon‑skipping drug program, with the agency expected to rule by the end of February. The timing is…
- Investors increase stakes in Bain-backed biotech startup as FDA gene‑therapy chief departsInvestors are putting more money into a biotech startup backed by private‑equity firm Bain Capital, according to the STAT+ newsletter. Vijay Kumar is leaving his role as acting director of the FDA…